Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that GlaxoSmithKline's ofatumumab will become Decision Resources' proprietary clinical gold-standard treatment for relapsed/refractory chronic lymphocytic leukemia (CLL) by 2012. This shift is due to ofatumumab's competitive advantages over the current gold standard--Bayer Schering Pharma's Campath/MabCampath--in efficacy (overall response rate), safety and tolerability (hematological toxicities and infections) and delivery (frequency).
The new report entitled Relapsed/Refractory Chronic Lymphocytic Leukemia: Physicians Are Eager for Increasingly Efficacious Therapies in the Refractory Setting finds that an agent showing improvement in overall response rate, compared to Campath/MabCampath, for high-risk, relapsed/refractory patients would earn a higher patient share in the U.S. (50 percent) than in Europe (40 percent). This is because European oncologists are more cost-conscious than U.S. physicians and such a drug would bear a slight price increase.
"The European market is more sensitive to increases in price than the U.S. market, and the price of Campath/MabCampath is already very high in both markets. Even though European oncologists forecast a more conservative patient share for such an agent, a patient share of 40 percent is considerable in the relapsed/refractory CLL market," stated Andrew Merron, Ph.D., analyst at Decision Resources.
About the Report
Relapsed/Refractory Chronic Lymphocytic Leukemia: Physicians Are Eager for Increasingly Efficacious Therapies in the Refractory Setting is a DecisionBase 2009 report. DecisionBase 2009 is a decision-support tool that provides in-depth analysis of unmet need, physician expectations of new therapies and commercial dynamics to help pharmaceutical companies optimize their investments in drug development.
The report can be purchased by contacting Decision Resources. Members of the media may request an interview with an analyst.
About Decision Resources
Decision Resources (www.DecisionResources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.
About Decision Resources, Inc.
Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.
All company, brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.
Natalia Morales Elizabeth Marshall Decision Resources Decision Resources, Inc. 781-296-2691 781-296-2563 firstname.lastname@example.org email@example.com
First Call Analyst:
SOURCE: Decision Resources
CONTACT: Natalia Morales of Decision Resources, +1-781-296-2691,
firstname.lastname@example.org, or Elizabeth Marshall of Decision Resources, Inc.,
Web Site: http://www.decisionresources.com/